Intensity Therapeutics grants 78,000 options to CEO
Intensity Therapeutics, Inc. reported that President and CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Intensity Therapeutics, Inc. reported that President and CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026. The options carry an exercise price of $4.90 per share and expire on July 16, 2036. They vest in four equal annual installments beginning July 16, 2026, subject to his continued service, and represent an acquisition of derivative securities rather than a market purchase or sale of common stock.
Insider Trade Summary
Grant/Award: 78,000 shares
Grant/Award
1 txn
Insider
BENDER LEWIS H
Role
President and CEO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy Common Stock) F1 | 78,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy Common Stock) — 78,000 contracts (Direct)
Holdings Before and After:
Stock Option (right to buy Common Stock), 0 to 78,000 contracts (Direct)
Footnotes (1)
- F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.
Key Figures
Stock options granted: 78,000 options
Exercise price: $4.90 per share
Options owned after grant: 78,000 options
+2 more
5 metrics
Stock options granted
78,000 options
Grant to President and CEO Lewis H. Bender on July 16, 2026
Exercise price
$4.90 per share
Exercise price for the granted stock options
Options owned after grant
78,000 options
Total derivative securities beneficially owned after the reported transaction
Vesting schedule
4 annual installments
Equal annual vesting installments beginning July 16, 2026
Option expiration date
July 16, 2036
Expiration date of the granted stock options
Key Terms
Stock Option, exercise price, expiration date, vest
4 terms
Stock Option financial
"Security title: Stock Option (right to buy Common Stock)"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
exercise price financial
"conversion_or_exercise_price: 4.9000"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-16"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vest financial
"This option will vest, subject to the individual's continued service"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did INTS report for Lewis H. Bender?
Intensity Therapeutics reported that CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026. These options relate to common stock, are compensation-based, and do not represent an open-market purchase or sale of shares.
What is the exercise price of the new stock options granted at INTS?
The granted stock options have an exercise price of $4.90 per share. This is the price at which Lewis H. Bender may purchase Intensity Therapeutics common stock upon exercising the options before their expiration date.
How do the INTS stock options granted to the CEO vest?
The 78,000 stock options granted to the INTS CEO vest in four equal annual installments beginning on July 16, 2026. Vesting is explicitly conditioned on his continued service with Intensity Therapeutics, Inc. through each vesting date.
When do the INTS CEO’s newly granted stock options expire?
The newly granted stock options to the INTS CEO expire on July 16, 2036. After that date, any unexercised options will lapse, and the right to purchase common stock at the $4.90 exercise price will terminate.
Is the INTS CEO’s option grant reported under a Rule 10b5-1 trading plan?
The filing indicates that the Rule 10b5-1 checkbox is not marked for this transaction. This suggests the reported option grant was not identified as made pursuant to a pre-arranged Rule 10b5-1 trading plan.
How many derivative securities does the INTS CEO hold after this grant?
Following this reported grant, Lewis H. Bender holds 78,000 stock options as derivative securities. This figure reflects the total options reported as beneficially owned after the July 16, 2026 transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
